No Data
Chiome Bioscience: Confirmation
Chiome Bioscience: Financial Report - Term 21 (2024/01/01 - 2024/12/31)
Chiome Bioscience: Interim report.
CINC, Good Patch and others.
The share buyback by CINCF has a maximum of 0.52 million shares (15.42% of the total shares issued) and will be purchased on the 19th through ToSTNeT-3. DWTI has completed the administration of the treatment for corneal endothelial degeneration, "K-321", in the Global Phase III clinical trial. KAIOM has signed a business partnership agreement with SRD, which handles clinical development and regulatory support for Pharmaceuticals and Medical Devices.
<Individual Stock Trends> Tekken Construction, Stem Inc, Kaiom, Kyowa Industrial, Electrical Utilities HD = 18th afternoon session.
Tekkou Construction <1815.T> - A total of 695,000 shares will be retired as of March 26, representing 4.44% of the issued shares before retirement. Stem Inc <3804.T> - The consolidated financial results for the first quarter of the fiscal year ending October 2025 (November 2024 - January 2025) landed with significant profit increases. Kaiom <4583.T> - A business partnership contract has been concluded with SRD (Chuo-ku, Tokyo) that supports the development of Pharmaceuticals. Kyowa Industry <5971.T> - Cumulative results for the third quarter of the fiscal year ending April 2025 (May 2024 - January 2025).
Chiome Bioscience Updates Financial Results for FY 2024